Elidel is named as an intervention in 2 current clinical trials in our Poland and Taiwan registers. None are recruiting at the moment. The most common phase is Not applicable. The sponsor with the most trials is Milosz Pietrus (1). The most-studied condition is Vulvar Lichen Sclerosus.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.
NCT07240389 · ClinicalTrials.gov ↗ · Vulvar Lichen Sclerosus
|
Not applicable | Not yet open | Milosz Pietrus | Poland |
|
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
NCT06052995 · ClinicalTrials.gov ↗ · Mild to Moderate Atopic Dermatitis
|
Observational | Active, closed | BGP Products Operations GmbH, a Viatris company | Taiwan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Milosz Pietrus | 1 |
| BGP Products Operations GmbH, a Viatris company | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Poland | 1 | 0 |
| Clinical trials in Taiwan | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Poland and Taiwan registers name Elidel as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Milosz Pietrus (1) and BGP Products Operations GmbH, a Viatris company (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Elidel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Elidel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Elidel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.